Daily Stock Analysis, CARA, Cara Therapeutics Inc, priceseries

Cara Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
19.00
Close
19.04
High
19.31
Low
18.37
Previous Close
18.91
Daily Price Gain
0.13
YTD High
20.85
YTD High Date
Apr 8, 2019
YTD Low
12.83
YTD Low Date
Jan 2, 2019
YTD Price Change
4.48
YTD Gain
30.77%
52 Week High
24.30
52 Week High Date
Sep 21, 2018
52 Week Low
11.50
52 Week Low Date
May 10, 2018
52 Week Price Change
6.56
52 Week Gain
52.56%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
9.76
Feb 10. 2017
15.27
27 Trading Days
56.45%
Link
LONG
Feb 24. 2017
15.03
Mar 10. 2017
16.08
10 Trading Days
6.97%
Link
LONG
Mar 22. 2017
16.09
Apr 3. 2017
18.00
8 Trading Days
11.84%
Link
LONG
Jan 19. 2018
13.00
Feb 1. 2018
14.17
9 Trading Days
9.00%
Link
LONG
Jun 4. 2018
15.54
Jun 22. 2018
16.61
14 Trading Days
6.87%
Link
LONG
Sep 7. 2018
19.93
Oct 2. 2018
22.77
17 Trading Days
14.26%
Link
LONG
Mar 11. 2019
17.13
Mar 22. 2019
18.69
9 Trading Days
9.11%
Link
Company Information
Stock Symbol
CARA
Exchange
NasdaqGM
Company URL
http://www.caratherapeutics.com
Company Phone
203-406-3700
CEO
Derek T. Chalmers
Headquarters
Connecticut
Business Address
4 STAMFORD PLAZA, 107 ELM STREET 9TH FLOOR, STAMFORD, CT 06902
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001346830
About

CARA Therapeutics, Inc. is a clinical-stage company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frédérique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Description

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The company's lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.